It can generate billions in revenue from both acute and possibly chronic pain. If approved, it would give Vertex ...
Orna Therapeutics and Vertex will use lipid nanoparticle system to develop gene-editing therapies for people with SCD and TDT ...
The "CRISPR-based Gene Editing Market by Product & Service, by Application, by End-User, and By Region" report has been added ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 43rd Annual J.P. Morgan Healthcare Conference January 13, 2025 10:30 AM ETCompany ParticipantsDr.
Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI's impact and Trump's second ...
Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...
However, this doesn't mean you can't have strong opinions about certain investments. I'm quite confident that some stocks will be winners over the long run. Here are my three highest-conviction growth ...
Vertex Pharmaceuticals Incorporated today announced multiple program updates ahead of upcoming investor meetings in January, including the company's scheduled webcast from the 43rd Annual J.P. Morgan ...
This Fool has his eye on an innovative growth stock that has plunged by 80% since early 2021. But what is so special about it ...
In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price ...
The Gates Foundation will invest up to $50 million to support Tessera's SCD gene editing treatment, the company said.
Last year, it declined by 37%. CRISPR and its development partner Vertex Pharmaceuticals have obtained approvals for their gene therapy treatment, Casgevy, to treat patients with sickle cell disease ...